Exhibit 99.1 Amarin Reports First Quarter 2024 Business Update and Financial Results -- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 '24 versus Q4 '23 Driven by Spain and the UK -- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Foll ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-21392 Amarin Corporation plc (Exact Name of Registrant as Specified in its Charter) England and Wales Not applicable (State or Other Jurisdict ...

Amarin公司请愿 - Amarin公司支持一项向FDA提交的请愿，要求FDA关注和采取进一步行动来解决非标签使用芬布拉酸盐的问题[1] - 芬布拉酸盐与他汀类药物联合使用在减少心血管疾病风险方面无临床益处，但在2023年仍有超过1100万处方和超过100万患者使用了芬布拉酸盐[1] FDA请愿要求 - HealthyWomen提交的请愿要求FDA修改芬布拉酸盐药物标签，包括最新临床研究结果，以及进一步澄清FDA之前采取的立场[3]

DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM). Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. compan ...

关于VASCEPA/VAZKEPA的研究结果 - REDUCE-IT研究显示,无论基线Lp(a)水平高低,使用VASCEPA/VAZKEPA均可显著降低主要不良心血管事件(MACE)的风险,高Lp(a)组(≥50 mg/dL)相对风险降低21%,低Lp(a)组(<50 mg/dL)相对风险降低25%[4][6] - 在基线LDL-C水平<55 mg/dL和≥55 mg/dL的患者中,使用VASCEPA/VAZKEPA均可显著降低心血管事件风险,分别降低34%和24%[11] - REDUCE-IT研究共纳入8,179名患者,中位随访4.9年,结果显示VASCEPA/VAZKEPA可显著降低主要不良心血管事件的发生风险[17] 关于VASCEPA/VAZKEPA的适应症和安全性 - VASCEPA/VAZKEPA适用于既往心血管疾病或2型糖尿病合并2个以上心血管危险因素的成人患者,作为最大耐受剂量他汀治疗的辅助治疗,以降低心肌梗死、卒中、冠状动脉重建和需住院的不稳定心绞痛的风险[20] - VASCEPA/VAZKEPA也适用于成人严重高三酰甘油血症(≥500 mg/dL)患者,作为饮食治疗的辅助,以降低三酰甘油水平[21] - VASCEPA/VAZKEPA使用可能增加房颤/房扑和出血的风险,需要密切监测[24][26]

Vazkepa专利保护期延长 - Amarin公司股价上涨7.1%，因为管理层宣布了关于其在欧洲唯一上市药物Vazkepa的知识产权组合的积极更新[1] - Amarin从欧洲专利局获得了一项新专利，为Vazkepa增加了另外八年的专利保护期，延长了该药物在欧洲的商业保护至2039年4月[2] - Amarin的股价上涨可能是因为Vazkepa的专利保护期延长，使得公司能够设定药物价格并受益于缺乏竞争[4] Vazkepa获得欧洲批准 - Vazkepa已获得欧洲批准，用于降低心血管事件的风险，如心脏病发作、中风和其他因血液循环受阻而引起的问题，也获得了作为附加治疗的批准，适用于正在接受他汀类药物治疗且血液中甘油三酯（TG）水平较高的成年人[5]

Amarin公司专利独家权延长 - Amarin公司的心血管药物Vazkepa在欧盟获得专利独家权延长，有效期延长至2039年[2] - 专利独家权对制药公司至关重要，可以更灵活地定价药物[3] - Amarin公司一直在积极捍卫Vazkepa/Vascepa的知识产权，最近在欧洲专利局的一场争议中取得胜利[4]

Amarin公司专利保护 - Amarin公司获得了欧洲专利局(EPO)的决定，将VAZKEPA的专利保护期延长至2039年[1] - 该决定涵盖了VAZKEPA在欧洲的使用，起源于REDUCE-IT心血管结果试验，为VAZKEPA在欧洲提供了更长的独家地位[2] - Amarin公司成功捍卫了另一项涵盖VAZKEPA的专利免受第三方反对，该专利有效期至2033年[3]

Amarin Corporation Plc (AMRN) reported break-even quarterly earnings in fourth-quarter 2023 against the Zacks Consensus Estimate of a loss of 4 cents per share. The company recorded adjusted earnings of 2 cents in the year-ago quarter. Adjusted earnings exclude non-cash stock-based compensation, restructuring inventory and other restructuring expenses. Total revenues were $74.7 million, beating the Zacks Consensus Estimate of $72.5 million. However, revenues were down 17% from the year-ago quarter’s levels, ...

Amarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Conference Call February 29, 2024 8:00 AM ET Company Participants Mark Marmur - Vice President, Global Corporate Communications Patrick Holt - President and Chief Executive Officer Tom Reilly - Executive Vice President, Chief Financial Officer and Head of Global HR & Finance Conference Call Participants Roanna Ruiz - Leerink Partners Operator Welcome to Amarin Corporation's Conference Call to discuss its Fourth Quarter and Full Year 2023 Financial Result ...